BIOLARGO, INC. - What You Need to Know

Thinking about investing in BioLargo? It is an interesting company, but you should look under the hood first. Here is the breakdown in plain English.

1. What does this company actually do?

Think of BioLargo as an "inventor’s workshop" for environmental and health issues. They develop, sell, and license their own technologies. Their core focus areas include:

• Cleaning Water: Their AEC technology is designed to remove "forever chemicals" (PFAS) from water. This is currently in the testing and development phase.
• Odor Control: Their flagship product, CupriDyne Clean, neutralizes odors for landfills and waste facilities.
• Advanced Wound Care: Their subsidiary, Clyra Medical, creates antimicrobial wound care products using iodine.
• New Tech: They are researching liquid sodium batteries for energy storage. The company hasn't provided much detail on the commercial timeline for this project yet.

2. How do they make money and are they growing?

They earn money by selling odor control products, providing consulting, and licensing their technology. While revenue has grown, the company is not yet profitable. They have a history of losing money and rely on outside funding to keep the lights on.

The "One Customer" Risk: One customer accounts for about 77% of their revenue. This customer distributes their pet odor control products. If this relationship ends or demand drops, BioLargo’s revenue would take a major hit. Also, odor control sales are seasonal. Demand peaks in warmer months, which causes revenue to jump and dip throughout the year.

3. What is this "Lincoln Park" deal?

BioLargo has a deal with Lincoln Park Capital Fund (LPC). Think of this as a line of credit for stock. BioLargo can sell up to $10 million worth of its own shares to LPC over three years. As of early 2025, they have used nearly $1 million and can still raise up to $8.8 million more.

4. What are the main risks?

• Dilution: Because the company isn't profitable, they often issue new shares to pay for operations. Every time they sell new shares, your ownership percentage shrinks, which can lower the stock price.
• "Penny Stock" Status: Trading around $0.23, the stock is a "penny stock." This brings strict regulations that can make it harder to trade and may lead some brokers to block purchases.
• Cybersecurity: A data breach could expose their research, damage their reputation, or cost them key partnerships.
• Internal Controls: The company admits its financial tracking systems are currently "not effective." This increases the risk of errors in their financial reports.
• Market Status: The stock trades on the OTCQX, not a major exchange like the Nasdaq. This means lower trading volume and less analyst coverage, making it harder to buy or sell quickly.

5. The Bottom Line

BioLargo is a high-risk, speculative bet. They are trying to sell complex technologies in tough markets, but they rely heavily on selling more shares to stay afloat. They have never paid a profit to shareholders and plan to reinvest any future earnings back into the business. Your potential return depends entirely on the success of their unproven tech and their ability to keep raising cash.

Before you decide:

• Check the Filings: Always read the "Risk Factors" section in their latest 10-K or 10-Q filings on the SEC website.
• Assess Your Risk: Small-cap stocks can be a wild ride. Never invest money you cannot afford to lose.
• Watch the Cash: Keep an eye on their quarterly reports to see how much of that Lincoln Park credit line they are using; it is a direct indicator of how much they are struggling to fund operations through sales alone.

Disclaimer: I am an AI, not a financial advisor. This guide is for informational purposes only and does not constitute financial advice. Always do your own research before making investment decisions.